Phaseline

Companies › Intra-Cellular Therapies

Intra-Cellular Therapies: clinical trials, targets and expected readouts

2 active drug programs in 17 registered trials: 9 Phase 3, 5 Phase 2, 3 Phase 4; Psychiatry, Neurology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
JNJ-99245354 (ITI-1284)
5-HT1A partial agonist
–Phase 3Generalized Anxiety Disorder; Agitation Associated With Alzheimer's Dementia; Psychotic DisordersMar 2027
Lumateperone
Serotonin 2a (5-HT2a) receptor antagonist; Dopamine D2 receptor antagonist; Serotonin transporter inhibitor
HTR2A, DRD2, SLC6A4Phase 3Major Depressive Disorder; Irritability Associated With Autism Spectrum Disorder; Bipolar Depression; Schizophrenia …Apr 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06174116LumateperonePhase 4SchizophreniaPsychiatryDec 2026
NCT06482554LumateperonePhase 3ApathyPsychiatryDec 2026
NCT06480383JNJ-99245354 (ITI-1284)Phase 2Generalized Anxiety DisorderPsychiatryMar 2027
NCT05850689LumateperonePhase 3Major Depressive DisorderPsychiatryApr 2027
NCT06690398LumateperonePhase 3Irritability Associated With Autism Spectrum DisorderPsychiatryJun 2027
NCT06706674LumateperonePhase 3Irritability Associated With Autism Spectrum DisorderPsychiatryJun 2027
NCT07734103LumateperonePhase 2Stuttering, AdultPsychiatryJul 2027
NCT06701903JNJ-99245354 (ITI-1284)Phase 2Generalized Anxiety DisorderPsychiatryOct 2027
NCT06651567JNJ-99245354 (ITI-1284)Phase 2Agitation Associated With Alzheimer's DementiaNeurologyDec 2027
NCT07699445LumateperonePhase 4Bipolar Depression Depressed PhasePsychiatryJan 2028
NCT07799493LumateperonePhase 4Social Anxiety Disorder (SAD)PsychiatryMay 2028
NCT07623135LumateperonePhase 3Treatment Resistant Depression (TRD)PsychiatryJun 2028
NCT06540833JNJ-99245354 (ITI-1284)Phase 2Psychotic DisordersNeurologySep 2028
NCT07807865JNJ-99245354 (ITI-1284)Phase 3Generalized Anxiety DisorderPsychiatryFeb 2030
NCT07856420JNJ-99245354 (ITI-1284)Phase 3Generalized Anxiety DisorderPsychiatrySep 2030
NCT06372964LumateperonePhase 3Bipolar DepressionPsychiatryOct 2031
NCT06229210LumateperonePhase 3SchizophreniaPsychiatryApr 2032

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

HTR2A (1) DRD2 (1) SLC6A4 (1)

Companies with the same targets

Otsuka Vanda Pharmaceuticals Definium Therapeutics US Sichuan Kelun Pharmaceutical Boryung Pharmaceutical Cybin IRL COMPASS Pathways ACADIA Pharmaceuticals NeuroRx Tonix Pharmaceuticals

Companies built like this

Cybin IRL Gedeon Richter Definium Therapeutics US LB Pharmaceuticals Sichuan Jishengtang Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.